Rheb binds and regulates the mTOR kinase

Xiaomeng Long, Yenshou Lin, Sara Ortiz-Vega, Kazuyoshi Yonezawa, Joseph Avruch

Research output: Contribution to journalArticle

608 Citations (Scopus)

Abstract

Background: The target of rapamycin (TOR), in complex with the proteins raptor and LST8 (TOR complex 1), phosphorylates the p70S6K and 4E-BP1 to promote mRNA translation. Genetic evidence establishes that TOR complex activity in vivo requires the small GTPase Rheb, and overexpression of Rheb can rescue TOR from inactivation in vivo by amino-acid withdrawal. The Tuberous Sclerosis heterodimer (TSC1/TSC2) functions as a Rheb GTPase activator and inhibits TOR signaling in vivo. Results: Here, we show that Rheb binds to the TOR complex specifically, independently of its ability to bind TSC2, through separate interactions with the mTOR catalytic domain and with LST8. Rheb binding to the TOR complex in vivo and in vitro does not require Rheb guanyl nucleotide charging but is modulated by GTP and impaired by certain mutations (Ile39Lys) in the switch 1 loop. Nucleotide-deficient Rheb mutants, although capable of binding mTOR in vivo and in vitro, are inhibitory in vivo, and the mTOR polypeptides that associate with nucleotide-deficient Rheb in vivo lack kinase activity in vitro. Reciprocally, mTOR polypeptides bound to Rheb(Gln64Leu), a mutant that is nearly 90% GTP charged, exhibit substantially higher protein kinase specific activity than mTOR bound to wild-type Rheb. Conclusions: The TOR complex 1 is a direct target of Rheb-GTP, whose binding enables activation of the TOR kinase.

Original languageEnglish
Pages (from-to)702-713
Number of pages12
JournalCurrent Biology
Volume15
Issue number8
DOIs
Publication statusPublished - 2005 Apr 26

Fingerprint

Sirolimus
phosphotransferases (kinases)
Phosphotransferases
nucleotides
guanosinetriphosphatase
polypeptides
Guanosine Triphosphate
mutants
sclerosis
birds of prey
Nucleotides
active sites
protein kinases
translation (genetics)
inactivation
GTP Phosphohydrolase Activators
mutation
Raptors
amino acids
70-kDa Ribosomal Protein S6 Kinases

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., & Avruch, J. (2005). Rheb binds and regulates the mTOR kinase. Current Biology, 15(8), 702-713. https://doi.org/10.1016/j.cub.2005.02.053

Rheb binds and regulates the mTOR kinase. / Long, Xiaomeng; Lin, Yenshou; Ortiz-Vega, Sara; Yonezawa, Kazuyoshi; Avruch, Joseph.

In: Current Biology, Vol. 15, No. 8, 26.04.2005, p. 702-713.

Research output: Contribution to journalArticle

Long, X, Lin, Y, Ortiz-Vega, S, Yonezawa, K & Avruch, J 2005, 'Rheb binds and regulates the mTOR kinase', Current Biology, vol. 15, no. 8, pp. 702-713. https://doi.org/10.1016/j.cub.2005.02.053
Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J. Rheb binds and regulates the mTOR kinase. Current Biology. 2005 Apr 26;15(8):702-713. https://doi.org/10.1016/j.cub.2005.02.053
Long, Xiaomeng ; Lin, Yenshou ; Ortiz-Vega, Sara ; Yonezawa, Kazuyoshi ; Avruch, Joseph. / Rheb binds and regulates the mTOR kinase. In: Current Biology. 2005 ; Vol. 15, No. 8. pp. 702-713.
@article{bcb584a00a9e46d2a6cc106553700d91,
title = "Rheb binds and regulates the mTOR kinase",
abstract = "Background: The target of rapamycin (TOR), in complex with the proteins raptor and LST8 (TOR complex 1), phosphorylates the p70S6K and 4E-BP1 to promote mRNA translation. Genetic evidence establishes that TOR complex activity in vivo requires the small GTPase Rheb, and overexpression of Rheb can rescue TOR from inactivation in vivo by amino-acid withdrawal. The Tuberous Sclerosis heterodimer (TSC1/TSC2) functions as a Rheb GTPase activator and inhibits TOR signaling in vivo. Results: Here, we show that Rheb binds to the TOR complex specifically, independently of its ability to bind TSC2, through separate interactions with the mTOR catalytic domain and with LST8. Rheb binding to the TOR complex in vivo and in vitro does not require Rheb guanyl nucleotide charging but is modulated by GTP and impaired by certain mutations (Ile39Lys) in the switch 1 loop. Nucleotide-deficient Rheb mutants, although capable of binding mTOR in vivo and in vitro, are inhibitory in vivo, and the mTOR polypeptides that associate with nucleotide-deficient Rheb in vivo lack kinase activity in vitro. Reciprocally, mTOR polypeptides bound to Rheb(Gln64Leu), a mutant that is nearly 90{\%} GTP charged, exhibit substantially higher protein kinase specific activity than mTOR bound to wild-type Rheb. Conclusions: The TOR complex 1 is a direct target of Rheb-GTP, whose binding enables activation of the TOR kinase.",
author = "Xiaomeng Long and Yenshou Lin and Sara Ortiz-Vega and Kazuyoshi Yonezawa and Joseph Avruch",
year = "2005",
month = "4",
day = "26",
doi = "10.1016/j.cub.2005.02.053",
language = "English",
volume = "15",
pages = "702--713",
journal = "Current Biology",
issn = "0960-9822",
publisher = "Cell Press",
number = "8",

}

TY - JOUR

T1 - Rheb binds and regulates the mTOR kinase

AU - Long, Xiaomeng

AU - Lin, Yenshou

AU - Ortiz-Vega, Sara

AU - Yonezawa, Kazuyoshi

AU - Avruch, Joseph

PY - 2005/4/26

Y1 - 2005/4/26

N2 - Background: The target of rapamycin (TOR), in complex with the proteins raptor and LST8 (TOR complex 1), phosphorylates the p70S6K and 4E-BP1 to promote mRNA translation. Genetic evidence establishes that TOR complex activity in vivo requires the small GTPase Rheb, and overexpression of Rheb can rescue TOR from inactivation in vivo by amino-acid withdrawal. The Tuberous Sclerosis heterodimer (TSC1/TSC2) functions as a Rheb GTPase activator and inhibits TOR signaling in vivo. Results: Here, we show that Rheb binds to the TOR complex specifically, independently of its ability to bind TSC2, through separate interactions with the mTOR catalytic domain and with LST8. Rheb binding to the TOR complex in vivo and in vitro does not require Rheb guanyl nucleotide charging but is modulated by GTP and impaired by certain mutations (Ile39Lys) in the switch 1 loop. Nucleotide-deficient Rheb mutants, although capable of binding mTOR in vivo and in vitro, are inhibitory in vivo, and the mTOR polypeptides that associate with nucleotide-deficient Rheb in vivo lack kinase activity in vitro. Reciprocally, mTOR polypeptides bound to Rheb(Gln64Leu), a mutant that is nearly 90% GTP charged, exhibit substantially higher protein kinase specific activity than mTOR bound to wild-type Rheb. Conclusions: The TOR complex 1 is a direct target of Rheb-GTP, whose binding enables activation of the TOR kinase.

AB - Background: The target of rapamycin (TOR), in complex with the proteins raptor and LST8 (TOR complex 1), phosphorylates the p70S6K and 4E-BP1 to promote mRNA translation. Genetic evidence establishes that TOR complex activity in vivo requires the small GTPase Rheb, and overexpression of Rheb can rescue TOR from inactivation in vivo by amino-acid withdrawal. The Tuberous Sclerosis heterodimer (TSC1/TSC2) functions as a Rheb GTPase activator and inhibits TOR signaling in vivo. Results: Here, we show that Rheb binds to the TOR complex specifically, independently of its ability to bind TSC2, through separate interactions with the mTOR catalytic domain and with LST8. Rheb binding to the TOR complex in vivo and in vitro does not require Rheb guanyl nucleotide charging but is modulated by GTP and impaired by certain mutations (Ile39Lys) in the switch 1 loop. Nucleotide-deficient Rheb mutants, although capable of binding mTOR in vivo and in vitro, are inhibitory in vivo, and the mTOR polypeptides that associate with nucleotide-deficient Rheb in vivo lack kinase activity in vitro. Reciprocally, mTOR polypeptides bound to Rheb(Gln64Leu), a mutant that is nearly 90% GTP charged, exhibit substantially higher protein kinase specific activity than mTOR bound to wild-type Rheb. Conclusions: The TOR complex 1 is a direct target of Rheb-GTP, whose binding enables activation of the TOR kinase.

UR - http://www.scopus.com/inward/record.url?scp=18044381192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044381192&partnerID=8YFLogxK

U2 - 10.1016/j.cub.2005.02.053

DO - 10.1016/j.cub.2005.02.053

M3 - Article

C2 - 15854902

AN - SCOPUS:18044381192

VL - 15

SP - 702

EP - 713

JO - Current Biology

JF - Current Biology

SN - 0960-9822

IS - 8

ER -